Biocon Share Price Jumps After Company Recieves USFDA Approval for 'Kristy'

Biocon share price saw a strong start to trading on July 16 as its stock climbed by nearly 3% in early trade. The jump in share price came after the company received approval from the United States Food & Drug Administration (USFDA) for its insulin product Kristy.

Kristy is a biosimilar of Insulin Aspart, a fast-acting insulin used to help control blood sugar levels in adults and children with diabetes. This approval marks a major milestone for Biocon as Kristy becomes the first and only interchangeable biosimilar to Novolog in the U.S.

Kristy: A Step Forward in Diabetes Care

Kristy will now be available in two formats:

• A single-patient-use prefilled pen for subcutaneous use
• A multiple-dose vial for both subcutaneous and intravenous use

Kristy was already being sold in the European Union and Canada since 2022, but the U.S. approval greatly expands its reach. According to 2024 IQVIA data, Novolog saw sales of US$1.19 billion in the U.S. market, making this a big opportunity for Biocon.

Biocon is Building on a Strong Portfolio

Biocon Biologics, the biosimilar arm of Biocon Ltd., already has a solid presence in the insulin market. Kristy will join the company’s existing portfolio, which includes Semglee—another FDA-approved interchangeable biosimilar of insulin glargine.

This development highlights Biocon’s continued push into global diabetes treatment markets and strengthens its position in the U.S., one of the world’s largest healthcare markets.

Biocon Share Price Performance

As of 2:14 PM on July 16, Biocon Ltd shares were trading at ₹394.90, up 1.14% or ₹4.45 from the previous close. The positive market response reflects investor confidence following the USFDA approval for Kristy. The stock earlier touched an intraday high of ₹405.90 and a low of ₹393.20 on the NSE.

Read more: Adani Group Recent Acquisitions Across Power, Ports, and Cement in H1 2025.

Conclusion

The USFDA approval for Kristy is a major achievement for Biocon. It not only adds to the company’s insulin portfolio but also opens up new growth opportunities in the U.S. Biocon’s focus on expanding its global reach through high-quality biosimilars continues to pay off.

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions.

Investments in the securities market are subject to market risks. Read all the related documents carefully before investing.